Lerdelimumab
Lerdelimumab
Lerdelimumab (pronounced: ler-del-im-u-mab) is a monoclonal antibody designed for the treatment of certain medical conditions. It is a type of biologic therapy that is used in the field of immunology and oncology.
Etymology
The name "Lerdelimumab" is derived from the International Nonproprietary Names (INNs), in which 'mab' at the end suggests it is a monoclonal antibody. 'Lerdeli' is the unique stem for this particular drug.
Usage
Lerdelimumab is used in the treatment of certain types of cancer and autoimmune diseases. It works by targeting specific proteins on the surface of cells, thereby helping the immune system to attack these cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Each monoclonal antibody is made so that it binds only to one substance.
- Biologic Therapy: Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments.
- Immunology: The branch of medicine and biology concerned with immunity.
- Oncology: The study and treatment of tumors.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Autoimmune Diseases: A condition arising from an abnormal immune response to a normal body part.
External links
- Medical encyclopedia article on Lerdelimumab
- Wikipedia's article - Lerdelimumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski